Gastroenteritis is a worldwide infectious disease problem that is the major cause of neonatal and infant mortality in developing countries and of significant morbidity in developed countries. Recognition that rotaviruses and enterotoxigenic Escherichia coli are the major agents that cause lifethreatening disease has focused vaccine development against these pathogens. The objective of the proposed work is to test the use of purified rotavirus capsid proteins as orally administered intestinal immunogens. This project will evaluate the ability of rotavirus capsid proteins (VP3, VP6 and VP-7) synthesized in high yields in a baculovirus expression system to induce a mucosal immune response and to be used as a vaccine. Purified expressed proteins will be evaluated as immunogens in two animals models of rotavirus gastroenteritis and in volunteers. Passive protection will be tested in a mouse model, active protection will be tested in a rabbit model, and the immunogenicity of vaccines found to be active in these animal models will will also be tested in volunteers. Vaccine dose, formulation (individual or mixtures of proteins), and type of adjuvant used for oral immunization will be evaluated to determine their effectiveness in stimulating both mucosal and systemic immunity and protection from virus challenge. These studies will directly assess the use of purified rotavirus proteins as rotavirus proteins as rotavirus subunit vaccines. The results will also be tested for their general applicability for the development and use of purified proteins from other enteric pathogens as mucosal vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI024998-04
Application #
3138275
Study Section
Virology Study Section (VR)
Project Start
1987-07-01
Project End
1992-06-30
Budget Start
1990-07-01
Budget End
1991-06-30
Support Year
4
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Miller, Amber D; Blutt, Sarah E; Conner, Margaret E (2014) FoxP3+ regulatory T cells are not important for rotavirus clearance or the early antibody response to rotavirus. Microbes Infect 16:67-72
Preidis, Geoffrey A; Keaton, Mignon A; Campeau, Philippe M et al. (2014) The undernourished neonatal mouse metabolome reveals evidence of liver and biliary dysfunction, inflammation, and oxidative stress. J Nutr 144:273-81
Killoran, Kristin E; Miller, Amber D; Uray, Karen S et al. (2014) Role of innate immunity and altered intestinal motility in LPS- and MnCl2-induced intestinal intussusception in mice. Am J Physiol Gastrointest Liver Physiol 306:G445-53
Lopatin, Uri; Blutt, Sarah E; Conner, Margaret E et al. (2013) Lymphotoxin alpha-deficient mice clear persistent rotavirus infection after local generation of mucosal IgA. J Virol 87:524-30
Preidis, Geoffrey A; Saulnier, Delphine M; Blutt, Sarah E et al. (2012) Host response to probiotics determined by nutritional status of rotavirus-infected neonatal mice. J Pediatr Gastroenterol Nutr 55:299-307
Blutt, S E; Miller, A D; Salmon, S L et al. (2012) IgA is important for clearance and critical for protection from rotavirus infection. Mucosal Immunol 5:712-9
Preidis, Geoffrey A; Saulnier, Delphine M; Blutt, Sarah E et al. (2012) Probiotics stimulate enterocyte migration and microbial diversity in the neonatal mouse intestine. FASEB J 26:1960-9
Williams, Kent; Koyama, Tatsuki; Schulz, Daryl et al. (2011) Use of fluoroscopy to study in vivo motility in mouse pups. J Pediatr Gastroenterol Nutr 52:679-85
Marcelin, Glendie; Miller, Amber D; Blutt, Sarah E et al. (2011) Immune mediators of rotavirus antigenemia clearance in mice. J Virol 85:7937-41
Blutt, Sarah E; Kirkwood, Carl D; Parreno, Viviana et al. (2003) Rotavirus antigenaemia and viraemia: a common event? Lancet 362:1445-9